X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEX) drug discovery platform to the generation of novel small molecule therapeutics, announced a drug discovery partnership with ALK-Abelló A/S (ALK), a Danish pharmaceutical company focused on the prevention and treatment of allergies.
Genprex, a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, provides a clinical update and focus for its Oncoprex immunogene therapy program for 2020, prioritizing the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC).
Aimmune Therapeutic has secured exclusive worldwide rights to Xencor’s XmAb 7195 for the development of next-generation food allergy treatments.
Regeneron Pharmaceuticals has expanded its collaboration with the US Department of Health and Human Services (HHS) to develop antibody treatments for novel coronavirus (2019-nCoV).
Bristol-Myers Squibb (BMS) and BioMotiv have launched a new biotechnology company, Anteros Pharmaceuticals, which will involve in the development of a new class of drugs for fibrotic and other inflammatory diseases.
US-based Catalent has agreed to acquire cell therapy company MaSTherCell Global for $315m in cash.
British drugmaker GlaxoSmithKline (GSK) has collaborated with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the novel Coronavirus (2019-nCoV).
Johnson & Johnson announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak.
Accenture has entered into a technology collaboration with Google Cloud with an objective to help life sciences companies advance the discovery, development, and delivery of their innovative therapies.
Alexion Pharmaceuticals has completed the acquisition of clinical-stage biopharmaceutical company Achillion Pharmaceuticals for around $930m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.